Previous 10 | Next 10 |
2023-04-19 09:15:00 ET British drugmaker AstraZeneca (NASDAQ: AZN) and U.S.-based Ionis Pharmaceuticals (NASDAQ: IONS) have been working jointly on a drug candidate for treating a rare disease known as transthyretin (ATTR) amyloidosis polyneuropathy. The potential medication...
2023-04-12 12:09:05 ET Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) jumped ~11% Wednesday after SVB Securities upgraded the RNAi therapeutics company to Outperform from Market Perform, citing an attractive risk-reward setup following the recent selloff. The analyst Mani Forooh...
2023-04-08 06:12:19 ET Summary Ionis has several revenue-generating therapies and two with pending PDUFA dates. Its phase 3 pipeline boasts five molecules with a sixth expected soon. An alluring business model is falling short for shareholders. A toxic mix of rising expens...
2023-04-06 11:51:32 ET Summary Ionis and Biogen have been partnering on antisense drug development for a decade. The two companies won approval for $1.8bn (in 2022) Spinraza, indicated for Spinal Muscular Atrophy. Tofersen, indicated for ALS, is not expected to generate peak r...
New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease PR Newswire Phase 1b study showed dose-dependent and sustained reduction of tau protein in cerebrospinal fluid through ...
2023-03-27 06:27:57 ET After a ~3% decline in the previous session, Incyte ( NASDAQ: INCY ) shares recovered in the pre-market trading Monday after announcing that the ministry of health in Japan approved its kinase inhibitor, Pemazyre, for bone cancer 8p11 myeloproliferative ...
Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN PR Newswire Eplontersen met co-primary endpoints demonstrating sustained reduction in TTR and benefits in neuropathy and quality of life through 66 weeks 35 and 66-week d...
Ionis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS PR Newswire If approved, tofersen will be the first treatment targeting a genetic cause of ALS and the next marketed Ionis-discovered antisense medicine ...
2023-03-22 18:05:49 ET Editor's note: This article was updated at 520p to reflect a second vote from the panel. An FDA advisory panel gave mixed signals Wednesday afternoon in two votes regarding Biogen ( NASDAQ: BIIB ) and Ionis Pharmaceuticals ( IONS ) amyot...
2023-03-22 17:06:31 ET An FDA advisory panel voted 9-0 that the data on Biogen ( NASDAQ: BIIB ) and Ionis Pharmaceuticals ( IONS ) amyotrophic lateral sclerosis (ALS) drug tofersen likely predicts it benefit. The recommendation from the Peripheral and Central...
News, Short Squeeze, Breakout and More Instantly...
Ionis Pharmaceuticals Inc. Company Name:
IONS Stock Symbol:
NASDAQ Market:
Ionis Pharmaceuticals Inc. Website:
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome PR Newswire ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set o...
Ionis to hold second quarter 2024 financial results webcast PR Newswire Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced ...
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease PR Newswire Zilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition...